A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
NCT05464719 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it is recruiting participants. It studies Loncastuximab tesirine in Large B-cell Lymphoma and Lymphoma. The registry lists an enrollment of 30 participants at 1 site in 1 country. The registry lists a start date of 23 Sept 2022 and a primary completion date of 30 Jan 2030.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05464719 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | M.D. Anderson Cancer Center |
| Enrollment | 30 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Large B-cell Lymphoma and Lymphoma |
| Drugs | Loncastuximab tesirine |
| Start | 23 Sept 2022 |
| Primary completion | 30 Jan 2030 |
| Study completion | 30 Jan 2030 |
| Last update posted | 15 Jul 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Paolo Strati, MD
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Md Anderson Cancer Center
Houston
Paolo Strati, MDRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05464719
Each answer restates registry values shown on this page.
What is NCT05464719?
NCT05464719 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. It studies Loncastuximab tesirine in Large B-cell Lymphoma and Lymphoma.
Is NCT05464719 recruiting?
As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.
Who leads NCT05464719?
The registry names Paolo Strati, MD (principal investigator, M.D. Anderson Cancer Center) as the overall official.
Where does NCT05464719 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT05464719 study?
The registered drug and biological interventions are Loncastuximab tesirine.
When is NCT05464719 expected to complete?
The registry lists a primary completion date of 30 Jan 2030 and a study completion date of 30 Jan 2030. The sponsor last updated the record on 15 Jul 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.